Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Department of Musculoskeletal and Plastic Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Acta Biomater. 2021 May;126:463-476. doi: 10.1016/j.actbio.2021.03.035. Epub 2021 Mar 25.
Critical-sized diaphysis defects are complicated by inherent sub-optimal healing conditions. The two-staged induced membrane technique has been used to treat these challenging defects since the 1980's. It involves temporary implantation of a membrane-inducing spacer and subsequent bone graft defect filling. A single-staged, graft-independent technique would reduce both socio-economic costs and patient morbidity. Our aim was to enable such single-staged approach through development of a strong bioactive glass scaffold that could replace both the spacer and the graft filling. We constructed amorphous porous scaffolds of the clinically used bioactive glass S53P4 and evaluated them in vivo using a critical-sized defect model in the weight-bearing femur diaphysis of New Zealand White rabbits. S53P4 scaffolds and standard polymethylmethacrylate spacers were implanted for 2, 4, and 8 weeks. Induced membranes were confirmed histologically, and their osteostimulative activity was evaluated through RT-qPCR of bone morphogenic protein 2, 4, and 7 (BMPs). Bone formation and osseointegration were examined using histology, scanning electron microscopy, energy-dispersive X-ray analysis, and micro-computed tomography imaging. Scaffold integration, defect union and osteosynthesis were assessed manually and with X-ray projections. We demonstrated that S53P4 scaffolds induce osteostimulative membranes and produce osseointegrative new bone formation throughout the scaffolds. We also demonstrated successful stable scaffold integration with early defect union at 8 weeks postoperative in critical-sized segmental diaphyseal defects with implanted sintered amorphous S53P4 scaffolds. This study presents important considerations for future research and the potential of the S53P4 bioactive glass as a bone substitute in large diaphyseal defects. STATEMENT OF SIGNIFICANCE: Surgical management of critical-sized diaphyseal defects involves multiple challenges, and up to 10% result in delayed or non-union. The two-staged induced membrane technique is successfully used to treat these defects, but it is limited by the need of several procedures and bone graft. Repeated procedures increase costs and morbidity, while grafts are subject to donor-site complications and scarce availability. To transform this two-staged technique into one graft-independent procedure, we developed amorphous porous scaffolds sintered from the clinically used bioactive glass S53P4. This work constitutes the first evaluation of such scaffolds in vivo in a critical-sized diaphyseal defect in the weight-bearing rabbit femur. We provide important knowledge and prospects for future development of sintered S53P4 scaffolds as a bone substitute.
临界尺寸骨干缺损复杂,存在固有愈合条件不佳的问题。自 20 世纪 80 年代以来,人们一直使用两阶段诱导膜技术来治疗这些具有挑战性的缺损。该技术涉及临时植入膜诱导间隔物和随后的骨移植物缺陷填充。单阶段、无移植物的技术将降低社会经济成本和患者发病率。我们的目标是通过开发一种强大的生物活性玻璃支架来实现这种单阶段方法,该支架可以替代间隔物和移植物填充。我们构建了临床使用的生物活性玻璃 S53P4 的非晶多孔支架,并在新西兰白兔承重股骨骨干的临界尺寸缺损模型中进行了体内评估。植入 S53P4 支架和标准聚甲基丙烯酸甲酯间隔物 2、4 和 8 周。通过 RT-qPCR 检测骨形态发生蛋白 2、4 和 7(BMPs),组织学证实诱导膜的形成,并评估其成骨刺激活性。使用组织学、扫描电子显微镜、能量色散 X 射线分析和微计算机断层扫描成像检查骨形成和骨整合。手动和 X 射线投影评估支架整合、缺损愈合和骨合成。我们证明 S53P4 支架可诱导成骨刺激膜,并在整个支架中产生骨整合的新骨形成。我们还证明了在植入烧结非晶 S53P4 支架的临界尺寸节段骨干缺损中,8 周术后早期即可成功稳定的支架整合和缺损愈合。这项研究为未来的研究提供了重要的考虑因素,并展示了 S53P4 生物活性玻璃作为大骨干缺损骨替代物的潜力。意义声明:临界尺寸骨干缺损的手术治疗涉及多个挑战,多达 10%的患者出现延迟愈合或不愈合。两阶段诱导膜技术成功地用于治疗这些缺损,但它受到需要多次手术和骨移植物的限制。重复手术增加了成本和发病率,而移植物会引起供体部位并发症和供应不足。为了将这种两阶段技术转化为无移植物的单一程序,我们开发了由临床使用的生物活性玻璃 S53P4 烧结而成的多孔非晶支架。这项工作首次在承重兔股骨的临界尺寸骨干缺损模型中对这种支架进行了体内评估。我们为未来烧结 S53P4 支架作为骨替代物的发展提供了重要的知识和前景。